ImaginAb, Inc. is a clinical-stage biotechnology company specializing in immune oncology imaging, with a focus on enhancing precision medicine for cancer treatment. Founded in 2007 and based in Inglewood, California, the company develops engineered antibody fragments known as minibodies, which are designed for diagnostic imaging using Positron Emission Tomography (PET). ImaginAb's portfolio includes precision imaging products targeting CD8 and CD4 for immune-oncology applications, as well as PSMA PET for prostate cancer diagnostics. By creating highly targeted diagnostic imaging agents that retain the specificity of parental antibodies while being optimized for clinical use, ImaginAb addresses critical needs in patient selection and treatment monitoring for cancer immunotherapy.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
ImaginAb, Inc. is a clinical-stage biotechnology company specializing in immune oncology imaging, with a focus on enhancing precision medicine for cancer treatment. Founded in 2007 and based in Inglewood, California, the company develops engineered antibody fragments known as minibodies, which are designed for diagnostic imaging using Positron Emission Tomography (PET). ImaginAb's portfolio includes precision imaging products targeting CD8 and CD4 for immune-oncology applications, as well as PSMA PET for prostate cancer diagnostics. By creating highly targeted diagnostic imaging agents that retain the specificity of parental antibodies while being optimized for clinical use, ImaginAb addresses critical needs in patient selection and treatment monitoring for cancer immunotherapy.
NanoSteel is an advanced materials company that specializes in the design and commercialization of innovative steel products with exceptional mechanical properties. Founded in 2002 and headquartered in Providence, Rhode Island, with additional offices in Michigan and Idaho, NanoSteel primarily focuses on developing proprietary alloys for lightweight automotive applications. The company's offerings include nanostructured steel sheets and powders designed for 3D printing and industrial processes, which enable automotive manufacturers to produce lighter vehicles more efficiently and cost-effectively. NanoSteel's products cater to various sectors, including automotive, ground transportation, tooling, and industrial markets, and are supported by over 300 patents globally. The company's advanced high strength steel (AHSS) materials are set to transform steel usage in the automotive industry, providing solutions that align with the growing demands for fuel economy and sustainability.
ClarVista Medical, Inc. is a California-based company that specializes in developing innovative products for ophthalmic conditions. Founded in 2012 as a spin-off from a medical device incubator, the company focuses on its flagship product, the HARMONI modular intraocular lens system. This system is designed to optimize vision during cataract surgery by allowing for the initial positioning of the lens and the easy exchange of the lens optic, thus enabling healthcare practitioners to tailor procedures to meet individual patient needs. ClarVista Medical has established a robust portfolio of intellectual property and has conducted clinical studies to validate its technology. The company has secured significant funding to advance the development of the HARMONI system and to pursue necessary regulatory approvals.
SOFIE brings that vision to life by increasing the adoption and application diversity of theranostics by removing the cost and complexity traditionally associated with the technology. With a full line of imaging and radiochemistry systems and a premier radiopharmacy network and contract manufacturing organization to supply novel agents for diagnosis and therapy, the company is dedicated to improving patient health.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
ImaginAb, Inc. is a clinical-stage biotechnology company specializing in immune oncology imaging, with a focus on enhancing precision medicine for cancer treatment. Founded in 2007 and based in Inglewood, California, the company develops engineered antibody fragments known as minibodies, which are designed for diagnostic imaging using Positron Emission Tomography (PET). ImaginAb's portfolio includes precision imaging products targeting CD8 and CD4 for immune-oncology applications, as well as PSMA PET for prostate cancer diagnostics. By creating highly targeted diagnostic imaging agents that retain the specificity of parental antibodies while being optimized for clinical use, ImaginAb addresses critical needs in patient selection and treatment monitoring for cancer immunotherapy.
SOFIE brings that vision to life by increasing the adoption and application diversity of theranostics by removing the cost and complexity traditionally associated with the technology. With a full line of imaging and radiochemistry systems and a premier radiopharmacy network and contract manufacturing organization to supply novel agents for diagnosis and therapy, the company is dedicated to improving patient health.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
OvaScience, Inc. was a fertility company dedicated to developing and commercializing innovative treatment options for women facing infertility challenges. The company focused on its patented technology involving the discovery of egg precursor (EggPC) cells, which aimed to transform fertility treatments. Key offerings included OvaPrime, which sought to restore egg production by utilizing a woman’s own EggPC cells; OvaTure, designed to mature these cells into fertilizable eggs outside the body; and AUGMENT, which enhanced fertilization and pregnancy rates by incorporating mitochondria from a woman’s EggPC cells. Founded in 2011 and headquartered in Waltham, Massachusetts, OvaScience was co-founded by notable figures from the life sciences field and was backed by prominent investors. In December 2018, OvaScience was acquired by Millendo Therapeutics in a reverse merger transaction.
ImaginAb, Inc. is a clinical-stage biotechnology company specializing in immune oncology imaging, with a focus on enhancing precision medicine for cancer treatment. Founded in 2007 and based in Inglewood, California, the company develops engineered antibody fragments known as minibodies, which are designed for diagnostic imaging using Positron Emission Tomography (PET). ImaginAb's portfolio includes precision imaging products targeting CD8 and CD4 for immune-oncology applications, as well as PSMA PET for prostate cancer diagnostics. By creating highly targeted diagnostic imaging agents that retain the specificity of parental antibodies while being optimized for clinical use, ImaginAb addresses critical needs in patient selection and treatment monitoring for cancer immunotherapy.
Private Equity Round in 2012
Iosil Energy Corporation specializes in the production and marketing of high-purity polysilicon, a critical raw material for solar cells. Founded in 2007 and headquartered in Groveport, Ohio, the company has established research and development facilities at the National Institute for Nanotechnology in Edmonton, Alberta. Iosil Energy utilizes innovative technology to purify silicon from waste material generated by wafer sawing operations, known as "kerf." This process not only enhances the purity of the polysilicon produced but also reduces energy consumption and equipment requirements, allowing for a more cost-effective solution for clients in the solar industry.
NanoSteel is an advanced materials company that specializes in the design and commercialization of innovative steel products with exceptional mechanical properties. Founded in 2002 and headquartered in Providence, Rhode Island, with additional offices in Michigan and Idaho, NanoSteel primarily focuses on developing proprietary alloys for lightweight automotive applications. The company's offerings include nanostructured steel sheets and powders designed for 3D printing and industrial processes, which enable automotive manufacturers to produce lighter vehicles more efficiently and cost-effectively. NanoSteel's products cater to various sectors, including automotive, ground transportation, tooling, and industrial markets, and are supported by over 300 patents globally. The company's advanced high strength steel (AHSS) materials are set to transform steel usage in the automotive industry, providing solutions that align with the growing demands for fuel economy and sustainability.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
SOFIE brings that vision to life by increasing the adoption and application diversity of theranostics by removing the cost and complexity traditionally associated with the technology. With a full line of imaging and radiochemistry systems and a premier radiopharmacy network and contract manufacturing organization to supply novel agents for diagnosis and therapy, the company is dedicated to improving patient health.
Solaria Corporation is a solar technology company that designs, develops, and manufactures silicon photovoltaic (PV) products aimed at solar system integrators, project developers, and large commercial and utility customers across the United States, Europe, and other international markets. The company produces crystalline solar modules suitable for various mounting systems and installation processes, as well as low-concentration solar PV cells. In addition to manufacturing, Solaria offers a range of services, including preliminary system design, energy yield optimization, and technical support throughout the installation process and beyond. Founded in 1993 and originally named Lightchip, Inc., Solaria changed its name in 2006 and is headquartered in Oakland, California, with additional offices in Germany and operations in India and China. The company's innovations aim to enhance energy production and reduce costs, facilitating access to clean and renewable energy sources.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
NanoSteel is an advanced materials company that specializes in the design and commercialization of innovative steel products with exceptional mechanical properties. Founded in 2002 and headquartered in Providence, Rhode Island, with additional offices in Michigan and Idaho, NanoSteel primarily focuses on developing proprietary alloys for lightweight automotive applications. The company's offerings include nanostructured steel sheets and powders designed for 3D printing and industrial processes, which enable automotive manufacturers to produce lighter vehicles more efficiently and cost-effectively. NanoSteel's products cater to various sectors, including automotive, ground transportation, tooling, and industrial markets, and are supported by over 300 patents globally. The company's advanced high strength steel (AHSS) materials are set to transform steel usage in the automotive industry, providing solutions that align with the growing demands for fuel economy and sustainability.
Alaunos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies aimed at treating heterogeneous solid tumors. The company utilizes innovative platform technologies, including the Sleeping Beauty system, which enables the genetic engineering of immune cells to enhance T-cell functionality for cancer treatment. Alaunos is advancing several therapies, notably Ad-RTS-hIL-12 combined with veledimex, which is currently in Phase 2 trials for recurrent glioblastoma multiforme. Additionally, the company is exploring chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies, leveraging collaborations with renowned institutions such as MD Anderson Cancer Center. The RheoSwitch Therapeutic System is another key technology employed by Alaunos, allowing for precise modulation of gene expression to improve cancer treatment outcomes. Founded in 1998 and based in Boston, Massachusetts, Alaunos is committed to advancing its portfolio of immuno-oncology solutions to address unmet medical needs in cancer care.
PsiloQuest
Series B in 2004
PsiloQuest develops and commercializes CMP polishing pads for the semiconductor industry.
Catalytic Solutions manufactures and distributes emissions control systems and catalytic products for commercial and industrial applications. It manufactures nanostructured catalysts at its main facility in Oxnard, California. The company’s products are most commonly applied to automobile, diesel engine, and energy markets. Catalytic Solutions has manufacturing facilities in Oxnard, California; Reno, Nevada; Thornhill, Canada; and Malmo, Sweden. Catalytic Solutions, Inc. operates as a subsidiary of Clean Diesel Technologies Inc.
Catalytic Solutions manufactures and distributes emissions control systems and catalytic products for commercial and industrial applications. It manufactures nanostructured catalysts at its main facility in Oxnard, California. The company’s products are most commonly applied to automobile, diesel engine, and energy markets. Catalytic Solutions has manufacturing facilities in Oxnard, California; Reno, Nevada; Thornhill, Canada; and Malmo, Sweden. Catalytic Solutions, Inc. operates as a subsidiary of Clean Diesel Technologies Inc.